Improved clinical, functional and work outcomes in
spondyloarthritides during real-life adalimumab treatment in
central-eastern Europe

J 2016

Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe

SZÁNTÓ, Sándor, Gyula POÓR, Daniela OPRIS, Oleg IAREMENKO, Leona PROCHÁZKOVÁ et. al.

Základní údaje

Originální název

Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe

Autoři

SZÁNTÓ, Sándor (348 Maďarsko), Gyula POÓR (348 Maďarsko), Daniela OPRIS (642 Rumunsko), Oleg IAREMENKO (804 Ukrajina), Leona PROCHÁZKOVÁ (203 Česká republika, garant, domácí), Reet KUUSE (233 Estonsko), Orsolya NAGY (348 Maďarsko), Valentyn CHERNYSHOV (112 Bělorusko) a Pál GÉHER (348 Maďarsko)

Vydání

Journal of Comparative Effectiveness Research, London, Future Medicine Ltd, 2016, 2042-6305

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.204

Kód RIV

RIV/00216224:14110/16:00092187

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.2217/cer-2016-0020

UT WoS

000380807700006

Klíčová slova anglicky

adalimumab; ankylosing spondylitis; extra-articular manifestations; observational study; psoriatic arthritis; workability

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 7. 12. 2016 11:29, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Aim: Adalimumab effectiveness on clinical, functional and work-related outcomes was evaluated in patients with active ankylosing spondylitis or psoriatic arthritis treated in routine clinical practice in central-eastern Europe. Methods: Patients (n = 555) were followed for 12 months. Primary end point was percentage of patients with a treatment response (>= 50% decrease from baseline in Bath Ankylosing Spondylitis Disease Activity Index or >= 1.2 point decrease from baseline in Disease Activity Index-28 joint for axial or peripheral symptoms, respectively). Functional status was evaluated by the Bath Ankylosing Spondylitis Functional Index and Health Assessment Questionnaire Disability Index. Working ability was evaluated by the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem. Results: 76.1% of patients with axial symptoms and 83.5% with peripheral symptoms achieved a treatment response. Frequency of extra-articular manifestations decreased. Improvements were observed in functional status and workability. No new safety signals were observed. Conclusion: Adalimumab was effective and well tolerated during real-world use in central-eastern Europe.

Citovat

SZÁNTÓ, Sándor, Gyula POÓR, Daniela OPRIS, Oleg IAREMENKO, Leona PROCHÁZKOVÁ, Reet KUUSE, Orsolya NAGY, Valentyn CHERNYSHOV a Pál GÉHER. Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe. Journal of Comparative Effectiveness Research. London: Future Medicine Ltd, 2016, roč. 5, č. 5, s. 475-485. ISSN 2042-6305. Dostupné z: https://dx.doi.org/10.2217/cer-2016-0020.

@article{1363876,
   author = {Szántó, Sándor and Poór, Gyula and Opris, Daniela and Iaremenko, Oleg and Procházková, Leona and Kuuse, Reet and Nagy, Orsolya and Chernyshov, Valentyn and Géher, Pál},
   article_location = {London},
   article_number = {5},
   doi = {http://dx.doi.org/10.2217/cer-2016-0020},
   keywords = {adalimumab; ankylosing spondylitis; extra-articular manifestations; observational study; psoriatic arthritis; workability},
   language = {eng},
   issn = {2042-6305},
   journal = {Journal of Comparative Effectiveness Research},
   title = {Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe},
   volume = {5},
   year = {2016}
}

TY  - JOUR
ID  - 1363876
AU  - Szántó, Sándor - Poór, Gyula - Opris, Daniela - Iaremenko, Oleg - Procházková, Leona - Kuuse, Reet - Nagy, Orsolya - Chernyshov, Valentyn - Géher, Pál
PY  - 2016
TI  - Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe
JF  - Journal of Comparative Effectiveness Research
VL  - 5
IS  - 5
SP  - 475-485
EP  - 475-485
PB  - Future Medicine Ltd
SN  - 20426305
KW  - adalimumab
KW  - ankylosing spondylitis
KW  - extra-articular manifestations
KW  - observational study
KW  - psoriatic arthritis
KW  - workability
N2  - Aim: Adalimumab effectiveness on clinical, functional and work-related outcomes was evaluated in patients with active ankylosing spondylitis or psoriatic arthritis treated in routine clinical practice in central-eastern Europe. Methods: Patients (n = 555) were followed for 12 months. Primary end point was percentage of patients with a treatment response (>= 50% decrease from baseline in Bath Ankylosing Spondylitis Disease Activity Index or >= 1.2 point decrease from baseline in Disease Activity Index-28 joint for axial or peripheral symptoms, respectively). Functional status was evaluated by the Bath Ankylosing Spondylitis Functional Index and Health Assessment Questionnaire Disability Index. Working ability was evaluated by the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem. Results: 76.1% of patients with axial symptoms and 83.5% with peripheral symptoms achieved a treatment response. Frequency of extra-articular manifestations decreased. Improvements were observed in functional status and workability. No new safety signals were observed. Conclusion: Adalimumab was effective and well tolerated during real-world use in central-eastern Europe.
ER  -

SZÁNTÓ, Sándor, Gyula POÓR, Daniela OPRIS, Oleg IAREMENKO, Leona PROCHÁZKOVÁ, Reet KUUSE, Orsolya NAGY, Valentyn CHERNYSHOV a Pál GÉHER. Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe. \textit{Journal of Comparative Effectiveness Research}. London: Future Medicine Ltd, 2016, roč.~5, č.~5, s.~475-485. ISSN~2042-6305. Dostupné z: https://dx.doi.org/10.2217/cer-2016-0020.

Podrobný výpis o publikaci